Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
467.35
+6.21 (1.35%)
At close: Jan 22, 2026, 4:00 PM EST
467.12
-0.23 (-0.05%)
After-hours: Jan 22, 2026, 6:48 PM EST
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,100 employees as of December 31, 2024. The number of employees increased by 700 or 12.96% compared to the previous year.
Employees
6,100
Change (1Y)
700
Growth (1Y)
12.96%
Revenue / Employee
$1,921,852
Profits / Employee
$602,475
Market Cap
117.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 6,100 | 700 | 12.96% |
| Dec 31, 2023 | 5,400 | 600 | 12.50% |
| Dec 31, 2022 | 4,800 | 900 | 23.08% |
| Dec 31, 2021 | 3,900 | 500 | 14.71% |
| Dec 31, 2020 | 3,400 | 400 | 13.33% |
| Dec 31, 2019 | 3,000 | 500 | 20.00% |
| Dec 31, 2018 | 2,500 | 200 | 8.70% |
| Dec 31, 2017 | 2,300 | 150 | 6.98% |
| Dec 31, 2016 | 2,150 | 200 | 10.26% |
| Dec 31, 2015 | 1,950 | 120 | 6.56% |
| Dec 31, 2014 | 1,830 | 30 | 1.67% |
| Dec 31, 2013 | 1,800 | -400 | -18.18% |
| Dec 31, 2012 | 2,200 | 200 | 10.00% |
| Dec 31, 2011 | 2,000 | 309 | 18.27% |
| Dec 31, 2010 | 1,691 | 259 | 18.09% |
| Dec 31, 2009 | 1,432 | 99 | 7.43% |
| Dec 31, 2008 | 1,333 | 183 | 15.91% |
| Dec 31, 2007 | 1,150 | 188 | 19.54% |
| Dec 31, 2006 | 962 | 149 | 18.33% |
| Dec 31, 2005 | 813 | 77 | 10.46% |
| Dec 31, 2004 | 736 | 12 | 1.66% |
| Dec 31, 2003 | 724 | -256 | -26.12% |
| Dec 31, 2002 | 980 | -20 | -2.00% |
| Dec 31, 2001 | 1,000 | 545 | 119.78% |
| Dec 31, 2000 | 455 | 102 | 28.90% |
| Dec 31, 1999 | 353 | 13 | 3.82% |
| Dec 31, 1998 | 340 | 120 | 54.55% |
| Dec 31, 1997 | 220 | 42 | 23.60% |
| Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,106 |
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Alnylam Pharmaceuticals | 2,230 |
| argenx SE | 1,599 |
VRTX News
- 2 days ago - Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - Business Wire
- 9 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - Business Wire
- 22 days ago - Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise - Seeking Alpha
- 4 weeks ago - Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 - Business Wire
- 5 weeks ago - Best Defensive Stocks To Balance Tech Sector Volatility - Seeking Alpha
- 5 weeks ago - Harbor Capital Appreciation Fund Q3 2025 Portfolio Review - Seeking Alpha
- 6 weeks ago - Vertex's gene therapy shows promise in younger children with blood disorders - Reuters